


PHARMACEUTICAL 2020



Cyclerion Therapeutics Inc. Rank 98 of 358





PHARMACEUTICAL 2020



Cyclerion Therapeutics Inc. Rank 98 of 358

The relative strengths and weaknesses of Cyclerion Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cyclerion Therapeutics Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Cyclerion Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is 162%, being 126% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	101,197
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,249
Liabilities, Non-Current	0
Other Assets	73,668
Other Compr. Net Income	-20
Other Expenses	0
Other Liabilities	0
Other Net Income	2,029
Other Revenues	4,507
Property and Equipment	11,613
Research and Development	95,140
Selling, General and Administrative Expense	34,404

Output Variable	Value in 1000 USD
Assets	186,478
Liabilities	18,249
Expenses	129,544
Revenues	4,507
Stockholders Equity	168,229
Net Income	-123,008
Comprehensive Net Income	-123,018
Economic Capital Ratio	162%

